TEC: Evidence Based Therapeutics
Therapeutics Education Collaboration
Medication Mythbusters – Home of the Best Science (BS) Medicine Podcast

Episode 290: PREMIUM – Empagliflozin and the EMPA-REG OUTCOME study

In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes. While this is a good finding, upcoming trials of other medications in this class will help put this drug into a context.

Show notes

1) EMPA-REG OUTCOME

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type-2 Diabetes

NEJM 2015 DOI: 10.1056/NEJMoa1504720 

See List of All Podcast Episodes

Search

BS Medicine Podcast

MEME 2023 Conference May 12-13, 2023

Making Evidence Matter For Everyone | May 12 & 13, 2023
From the clinicians who brought you the Best Science Medicine Course and the Meds Conference, as well as the BS Medicine Podcast and Tools for Practice

hectalks.com

BIG ANNOUNCEMENT

THE NUTRITION PROPOSITION BOOK HAS JUST BEEN RELEASED

Check it out at nutritionproposition.com and think about picking up a copy on Amazon. All the evidence you ever wanted about nutrition and the only nutrition book that won’t tell you what to eat.

 

BedMed: The High Blood Pressure Study

This pragmatic trial is now recruiting in BC. Make a difference and get involved with pragmatic trials (www.pragmatictrials.ca)

PEER Tools

Search

Recent Posts

Archives

Categories

Meta